Business
Press Release May 05 2025
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma".
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":" Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2025, titled \"Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma\". View Attachment","length":405,"tagName":"div"}]